The
work is aimed at shedding more light on known threats and,
potentially, emerging ones, the team at the Wellcome Sanger
Institute, working with the UK Health Security Agency, said.
The world has never had access to the kind of real-time
information for these viruses that scientists obtained on
SARS-CoV-2 through sequencing millions of genomes, Ewan
Harrison, head of the new Respiratory Virus and Microbiome
Initiative, told reporters on Monday.
That includes granular detail on how they transmit as well as
how they evolve in the face of the human immune response.
"We hope that by expanding our ability to sequence these viruses
routinely, we can build upon the work that's going on COVID, and
hopefully supercharge research efforts to understand the
transmission of these viruses, but also to help develop new
treatments and vaccines," Harrison said.
The aim is to make genomic surveillance of this type the norm,
to inform public health responses and act as a blueprint for
other countries that want to do the same thing, he said.
The work will begin later this year by using leftover material
from swabs taken for COVID-19 diagnostic purposes, sequencing
SARS-CoV-2, influenza, RSV and other common respiratory viruses
in a combined process.
While some of the viruses targeted typically cause mild,
cold-like symptoms, others can cause serious illness,
particularly in vulnerable populations.
Cases of COVID-19, flu and RSV have all surged this winter in
the northern hemisphere in a so-called "tripledemic" that is
putting serious pressure on hospitals in a number of countries.
The team said that, in future, the initiative could answer
questions about outbreaks like this.
It also aims to sequence everything found in a single nose swab,
including the viral, bacterial and fungal species present and
how they change during infection.
The five-year initiative aims to begin work from spring this
year and is funded by Wellcome.
(Reporting by Jennifer Rigby; Editing by Nick Macfie)
[© 2023 Thomson Reuters. All rights
reserved.] Copyright 2022 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|